Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
Jessica B Kendrick,Meijiao Zhou,Linda H Ficociello,Vidhya Parameswaran,Claudy Mullon,Michael S Anger,Daniel W Coyne
DOI: https://doi.org/10.2147/IJNRD.S353213
2022-04-12
International Journal of Nephrology and Renovascular Disease
Abstract:Jessica B Kendrick, 1 Meijiao Zhou, 2 Linda H Ficociello, 2 Vidhya Parameswaran, 2 Claudy Mullon, 2 Michael S Anger, 2, 3 Daniel W Coyne 4 1 University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 2 Fresenius Medical Care Global Medical Office, Waltham, MA, USA; 3 Unversity of Colorado School of Medicine, Denver, CO, USA; 4 Washington University School of Medicine, St. Louis, MO, USA Correspondence: Daniel W Coyne, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO, 63110, USA, Tel +1 314-362-7603, Fax +1 314-747-5213, Email Purpose: In prior analyses of real-world cohorts of hemodialysis patients switched from one phosphate binder (PB) to sucroferric oxyhydroxide (SO), SO therapy has been associated with improvements in serum phosphorus (sP) and reductions in daily PB pill burden. To characterize how SO initiation patterns have changed over time, we examined the long-term effectiveness of SO in a contemporary (2018– 2019) cohort. Patients and Methods: Adult Fresenius Kidney Care hemodialysis patients first prescribed SO monotherapy as part of routine care between May 2018 and May 2019 (N = 1792) were followed for 1 year. All patients received a non-SO PB during a 91-day baseline period before SO prescription. Mean PB pills/day and laboratory parameters were compared before and during SO treatment. Results were divided into consecutive 91-day intervals (Q1–Q4) and analyzed using linear mixed-effects regression and Cochran's Q test. These results were contrasted with findings from a historical (2014– 2015) cohort (N = 530). Results: The proportion of patients achieving sP ≤ 5.5 mg/dl increased after switching to SO (from 27.0% at baseline to 37.8%, 45.1%, 44.7%, and 44.0% at Q1, Q2, Q3, and Q4, respectively; P < 0.0001 for all). The mean daily PB pill burden decreased from a baseline of 7.7 to 4.4, 4.6, 4.8, and 4.9, respectively, across quarters ( P < 0.0001 for all). Patients in the contemporary cohort had improved sP control (27.0% achieving sP ≤ 5.5 mg/dl vs 17.7%) and lower daily PB pill burden (mean 7.7 vs 8.5 pills/day) at baseline than those in the historical cohort. Overall use of active vitamin D was similar between cohorts, although higher use of oral active vitamin D (63.9% vs 15.7%) and lower use of IV active vitamin D lower (23.4% vs 74.2%) was observed in the contemporary cohort. Conclusion: Despite evolving treatment patterns, switching to SO resulted in improved sP control with fewer pills per day in this contemporary hemodialysis cohort. Keywords: sucroferric oxyhydroxide, hemodialysis, pill burden, serum phosphorus, phosphate binder Hyperphosphatemia is a common complication of advanced chronic kidney disease (CKD), accompanied by hypocalcemia and low serum levels of vitamin D that often lead to secondary hyperparathyroidism and defects in bone mineral metabolism. 1 Without treatment, high serum phosphorus (sP) levels are associated with increased cardiovascular morbidity and mortality. 1–3 Because dietary phosphate restriction and dialysis treatment are often inadequate to manage hyperphosphatemia, administration of oral phosphate binders (PBs) that limit phosphorus absorption from ingested food is essential to maintain sP levels for most CKD patients on dialysis. 4,5 Both calcium-based binders (eg, calcium acetate and calcium carbonate) and non–calcium-based binders, including sevelamer, lanthanum carbonate, and iron-based binders (eg, sucroferric oxyhydroxide and ferric citrate), have been shown to effectively lower sP levels. 6,7 However, most PBs are associated with high daily pill burden (hereinafter "pill burden") and low treatment adherence, which can in turn lead to increased sP concentrations. 8,9 Additionally, high doses of calcium-based binders are associated with an increased risk of hypercalcemia, vascular calcification, and cardiovascular disease. 10,11 Sucroferric oxyhydroxide (SO; Velphoro ® , Fresenius Medical Care Renal Therapies Group, Waltham, MA, USA) is a non-calcium, chewable, iron-based PB indicated for the treatment of hyperphosphatemia in CKD patients undergoing dialysis. 12 Clinical trial and real-world data have demonstrated the effectiveness of SO in managing sP levels with reduced pill burdens among dialysis patients. 12–14 Previous real-world evidence includes data from a large (N = 530) cohort analysis of patients prescribed SO within the first 2 years following SO availability in the United States (2014 cohort). 14 Within a year of switching to SO, the proportion of patients in this cohort achieving -Abstract Truncated-